Aileron Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 15
- Market Cap
- $52.4M
- Website
- http://www.aileronrx.com
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
Phase 1
Terminated
- Conditions
- Prevention of Chemotherapy-induced Myelosuppression
- Interventions
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Aileron Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05622058
- Locations
- 🇧🇬
MBAL University Hospital OOD, Panagyurishte, Bulgaria
🇺🇸Southern Oncology Specialists, Huntersville, North Carolina, United States
🇺🇸Oncology and Hematology Associates of West Broward, Tamarac, Florida, United States
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
Phase 1
Terminated
- Conditions
- Small-cell Lung CancerNon Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Aileron Therapeutics, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT04022876
- Locations
- 🇺🇸
Mount Sinai Cancer Research Program, Miami, Florida, United States
🇺🇸Regional Medical Oncolgy Center, Wilson, North Carolina, United States
🇺🇸Gabrail Cancer Institute, Canton, Ohio, United States
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Phase 1
Completed
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- Drug: ALRN-6924 in combination with cytarabine
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Aileron Therapeutics, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT02909972
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2020-07-14
- Lead Sponsor
- Aileron Therapeutics, Inc.
- Target Recruit Count
- 149
- Registration Number
- NCT02264613
Phase 1 Safety Study of ALRN-5281 in Healthy Subjects
Phase 1
Completed
- Conditions
- Growth Hormone Deficiency
- Interventions
- Drug: ALRN-5281 0.15 mg/kgDrug: ALRN-5281 0.015 mg/kgDrug: ALRN-5281 0.05 mg/kgDrug: Placebo 0.015 mg/kgDrug: Placebo 0.05mg/kgDrug: Placebo 0.15mg/kg
- First Posted Date
- 2013-01-25
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Aileron Therapeutics, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT01775358
- Locations
- 🇺🇸
Vince and Associates Clinical Research, LLC, Overland Park, Kansas, United States
© Copyright 2025. All Rights Reserved by MedPath